These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 16550922)

  • 1. Animal model of oculopharyngeal muscular dystrophy.
    Uyama E; Hino H; Araki K; Takeya M; Uchino M; Yamamura K
    Acta Myol; 2005 Oct; 24(2):84-8. PubMed ID: 16550922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myopathy phenotype in transgenic mice expressing mutated PABPN1 as a model of oculopharyngeal muscular dystrophy.
    Hino H; Araki K; Uyama E; Takeya M; Araki M; Yoshinobu K; Miike K; Kawazoe Y; Maeda Y; Uchino M; Yamamura K
    Hum Mol Genet; 2004 Jan; 13(2):181-90. PubMed ID: 14645203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Doxycycline attenuates and delays toxicity of the oculopharyngeal muscular dystrophy mutation in transgenic mice.
    Davies JE; Wang L; Garcia-Oroz L; Cook LJ; Vacher C; O'Donovan DG; Rubinsztein DC
    Nat Med; 2005 Jun; 11(6):672-7. PubMed ID: 15864313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trehalose reduces aggregate formation and delays pathology in a transgenic mouse model of oculopharyngeal muscular dystrophy.
    Davies JE; Sarkar S; Rubinsztein DC
    Hum Mol Genet; 2006 Jan; 15(1):23-31. PubMed ID: 16311254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of PABPN1 nuclear inclusions on a large cohort of patients and in a human xenograft model of oculopharyngeal muscular dystrophy.
    Roth F; Dhiab J; Boulinguiez A; Mouigni HR; Lassche S; Negroni E; Muraine L; Marhic A; Oliver A; Lainé J; Rouche A; O'Ferrall EK; van Engelen B; Ottenheijm C; Greif H; Blumen S; Lacau St Guily J; Perie S; Butler-Browne G; Mouly V; Trollet C
    Acta Neuropathol; 2022 Dec; 144(6):1157-1170. PubMed ID: 36197469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mitochondrial localization of PABPN1 in oculopharyngeal muscular dystrophy.
    Doki T; Yamashita S; Wei FY; Hara K; Yamamoto T; Zhang Z; Zhang X; Tawara N; Hino H; Uyama E; Kurashige T; Maruyama H; Tomizawa K; Ando Y
    Lab Invest; 2019 Nov; 99(11):1728-1740. PubMed ID: 30894671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel mouse models of oculopharyngeal muscular dystrophy (OPMD) reveal early onset mitochondrial defects and suggest loss of PABPN1 may contribute to pathology.
    Vest KE; Phillips BL; Banerjee A; Apponi LH; Dammer EB; Xu W; Zheng D; Yu J; Tian B; Pavlath GK; Corbett AH
    Hum Mol Genet; 2017 Sep; 26(17):3235-3252. PubMed ID: 28575395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular and phenotypic characterization of a mouse model of oculopharyngeal muscular dystrophy reveals severe muscular atrophy restricted to fast glycolytic fibres.
    Trollet C; Anvar SY; Venema A; Hargreaves IP; Foster K; Vignaud A; Ferry A; Negroni E; Hourde C; Baraibar MA; 't Hoen PA; Davies JE; Rubinsztein DC; Heales SJ; Mouly V; van der Maarel SM; Butler-Browne G; Raz V; Dickson G
    Hum Mol Genet; 2010 Jun; 19(11):2191-207. PubMed ID: 20207626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oculopharyngeal muscular dystrophy: recent advances in the understanding of the molecular pathogenic mechanisms and treatment strategies.
    Abu-Baker A; Rouleau GA
    Biochim Biophys Acta; 2007 Feb; 1772(2):173-85. PubMed ID: 17110089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of oculopharyngeal muscular dystrophy-associated aggregation of nuclear polyA-binding protein with a single-domain intracellular antibody.
    Verheesen P; de Kluijver A; van Koningsbruggen S; de Brij M; de Haard HJ; van Ommen GJ; van der Maarel SM; Verrips CT
    Hum Mol Genet; 2006 Jan; 15(1):105-11. PubMed ID: 16319127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progressive myopathy in an inducible mouse model of oculopharyngeal muscular dystrophy.
    Mankodi A; Wheeler TM; Shetty R; Salceies KM; Becher MW; Thornton CA
    Neurobiol Dis; 2012 Jan; 45(1):539-46. PubMed ID: 21964252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HnRNP A1 and A/B interaction with PABPN1 in oculopharyngeal muscular dystrophy.
    Fan X; Messaed C; Dion P; Laganiere J; Brais B; Karpati G; Rouleau GA
    Can J Neurol Sci; 2003 Aug; 30(3):244-51. PubMed ID: 12945950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progress in understanding the pathogenesis of oculopharyngeal muscular dystrophy.
    Fan X; Rouleau GA
    Can J Neurol Sci; 2003 Feb; 30(1):8-14. PubMed ID: 12619777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oculopharyngeal muscular dystrophy: phenotypic and genotypic characteristics of 9 Polish patients.
    Nadaj-Pakleza A; Richard P; Lusakowska A; Gajewska J; Jamrozik Z; Kostera-Pruszczyk A; Kwieciński H; Kamińska A
    Neurol Neurochir Pol; 2009; 43(2):113-20. PubMed ID: 19484687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Established PABPN1 intranuclear inclusions in OPMD muscle can be efficiently reversed by AAV-mediated knockdown and replacement of mutant expanded PABPN1.
    Malerba A; Klein P; Lu-Nguyen N; Cappellari O; Strings-Ufombah V; Harbaran S; Roelvink P; Suhy D; Trollet C; Dickson G
    Hum Mol Genet; 2019 Oct; 28(19):3301-3308. PubMed ID: 31294444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytoplasmic targeting of mutant poly(A)-binding protein nuclear 1 suppresses protein aggregation and toxicity in oculopharyngeal muscular dystrophy.
    Abu-Baker A; Laganiere S; Fan X; Laganiere J; Brais B; Rouleau GA
    Traffic; 2005 Sep; 6(9):766-79. PubMed ID: 16101680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nuclear entrapment and extracellular depletion of PCOLCE is associated with muscle degeneration in oculopharyngeal muscular dystrophy.
    Raz V; Sterrenburg E; Routledge S; Venema A; van der Sluijs BM; Trollet C; Dickson G; van Engelen BG; van der Maarel SM; Antoniou MN
    BMC Neurol; 2013 Jul; 13():70. PubMed ID: 23815790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oculopharyngeal muscular dystrophy: potential therapies for an aggregate-associated disorder.
    Davies JE; Berger Z; Rubinsztein DC
    Int J Biochem Cell Biol; 2006; 38(9):1457-62. PubMed ID: 16530457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Wild-type PABPN1 is anti-apoptotic and reduces toxicity of the oculopharyngeal muscular dystrophy mutation.
    Davies JE; Sarkar S; Rubinsztein DC
    Hum Mol Genet; 2008 Apr; 17(8):1097-108. PubMed ID: 18178579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atrophy, fibrosis, and increased PAX7-positive cells in pharyngeal muscles of oculopharyngeal muscular dystrophy patients.
    Gidaro T; Negroni E; Perié S; Mirabella M; Lainé J; Lacau St Guily J; Butler-Browne G; Mouly V; Trollet C
    J Neuropathol Exp Neurol; 2013 Mar; 72(3):234-43. PubMed ID: 23399899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.